

Appendix Table F80. Blurred vision after pharmacological treatments for UI when compared to each other

Reference	Active drug	Dose	Control drug	Dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute rRisk difference (95% CI)
Zinner, 2005 ⁴¹²	Darifenacin ER	15mg/day	Oxybutynin	5 mg 3 times/day	0/19	1/19	0.3(0.01; 7.7)	-0.05 (-0.19; 0.08)
Chapple, 2004 ²⁶⁵	Solifenacin	2.5mg once daily	Tolterodine	2mg twice daily	1/41	0/37	2.7(0.1; 64.6)	0.02 (-0.04; 0.09)
Chapple, 2004 ²⁶⁵	Solifenacin	5mg once daily	Tolterodine	2mg twice daily	1/37	0/37	3.0(0.1; 71.3)	0.03 (-0.04; 0.10)
Chapple, 2004 ²⁶⁵	Solifenacin	10mg once daily	Tolterodine	2mg twice daily	5/35	0/37	11.6(0.7; 202.5)	0.14 (0.02; 0.27)
Chapple, 2004 ²⁶⁵	Solifenacin	20mg once daily	Tolterodine	2mg twice daily	5/37	0/37	11.0(0.6; 192.1)	0.14 (0.02; 0.25)
Chapple, 2004 ⁵⁴	Solifenacin	5mg daily	Tolterodine	2mg twice daily	10/279	4/266	2.4(0.8; 7.5)	0.02 (-0.01; 0.05)
Chapple, 2004 ⁵⁴	Solifenacin	10mg daily	Tolterodine	2mg twice daily	15/269	4/266	3.7(1.2; 11.0)	0.04 (0.01; 0.07)
Zinner, 2005 ⁴¹²	Darifenacin ER	30mg/day	Oxybutynin	5 mg 3 times/day	0/19	1/19	0.3(0.0; 7.7)	-0.05 (-0.19; 0.08)
Chapple, 2007 ²⁶³	Solifenacin	5mg daily	Tolterodine	4mg daily	1/578	7/599	0.1(0.0; 1.2)	-0.01 (-0.02; 0.00)
Yamaguchi, 2007 ⁴¹⁰	Solifenacin	5mg daily	Propiverine	20mg daily	7/400	15/402	0.5(0.2; 1.1)	-0.02 (-0.04; 0.00)
Yamaguchi, 2007 ⁴¹⁰	Solifenacin	10mg daily	Propiverine	20mg daily	16/385	15/402	1.1(0.6; 2.2)	0.00 (-0.02; 0.03)
Milani, 1993 ³⁴⁸	Flavoxate	1200	Oxybutynin	5mg t.i.d.	1/50	2/50	0.5(0.0; 5.3)	-0.02 (-0.09; 0.05)
NCT00444925, ⁵⁸	Fesoterodine	4 to 8mg once daily	Tolterodine ER	4 to 8mg once daily	12/685	8/690	1.5(0.6; 3.7)	0.01 (-0.01; 0.02)
Armstrong, 2007 ²³²	Oxybutynin	10mg qd	Tolterodine ER	4mg qd	10/576	4/399	1.7(0.5; 5.5)	0.01 (-0.01; 0.02)

Bold - significant differences at 95%confidence level